Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

6.73
-0.2100-3.03%
Post-market: 6.730.00000.00%17:20 EDT
Volume:390.89K
Turnover:2.64M
Market Cap:448.22M
PE:-5.69
High:7.00
Open:6.93
Low:6.68
Close:6.94
52wk High:15.74
52wk Low:2.32
Shares:66.60M
Float Shares:39.39M
Volume Ratio:0.26
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1819
EPS(LYR):-1.1819
ROE:-25.30%
ROA:-16.90%
PB:1.28
PE(LYR):-5.69

Loading ...

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Jan 07

Chief Legal Officer Curt Oltmans Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 18, 2025

Fulcrum Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Dec 12, 2025

RA Capital Management Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 11, 2025

BRIEF-Fulcrum Therapeutics Announces Pricing Of Upsized $175.0 Million Public Offering Of Common Stock And Pre-Funded Warrants

Reuters
·
Dec 10, 2025

Fulcrum Therapeutics Inc - Prices Public Offering of 11.85 Mln Shares at $13.50

THOMSON REUTERS
·
Dec 10, 2025

Fulcrum Therapeutics Is Maintained at Underperform by B of A Securities

Dow Jones
·
Dec 10, 2025

BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale

Reuters
·
Dec 09, 2025

Press Release: Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

Dow Jones
·
Dec 09, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart

Reuters
·
Dec 09, 2025

Fulcrum Therapeutics Up Nearly 59%, on Pace for Largest Percent Increase Since August 2021 -- Data Talk

Dow Jones
·
Dec 09, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix

Reuters
·
Dec 08, 2025

BUZZ-Fulcrum Therapeutics rises after trial data of blood disorder drug

Reuters
·
Dec 08, 2025

Fulcrum Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 08, 2025

Fulcrum Therapeutics Shares up 49.1% Premarket After Positive Early-Stage Trial Data of Blood Disorder Drug

THOMSON REUTERS
·
Dec 08, 2025

RBC Raises Price Target on Fulcrum Therapeutics to $10 From $7, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Dec 08, 2025

Fulcrum Therapeutics Inc : Leerink Partners Raises Target Price to $24 From $20

THOMSON REUTERS
·
Dec 08, 2025

Fulcrum Shares Soar on Sickle-Cell Treatment Trial Results

Dow Jones
·
Dec 08, 2025

Fulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell

MT Newswires Live
·
Dec 08, 2025

Fulcrum Therapeutics Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease

Reuters
·
Dec 07, 2025